Author: Mark S. Marley

Images from the Hubble Space Telescope reveal a Jupiter-sized planet, perhaps with a surrounding dust disk, orbiting about 115 astronomical units from a nearby main sequence star.

Authors: Paul Kalas, James R. Graham, Eugene Chiang, Michael P. Fitzgerald, Mark Clampin, Edwin S. Kite, Karl Stapelfeldt, Christian Marois, John Krist

Infrared images from the Keck and Gemini telescopes reveal three giant planets orbiting counterclockwise around a young star, in a scaled-up version of our solar system.

Authors: Christian Marois, Bruce Macintosh, Travis Barman, B. Zuckerman, Inseok Song, Jennifer Patience, David Lafrenière, René Doyon

In some human prostate cancers, a genomic deletion eliminates a key regulatory microRNA, which results in disruption of gene silencing mechanisms.

Authors: Sooryanarayana Varambally, Qi Cao, Ram-Shankar Mani, Sunita Shankar, Xiaosong Wang, Bushra Ateeq, Bharathi Laxman, Xuhong Cao, Xiaojun Jing, Kalpana Ramnarayanan, J. Chad Brenner, Jindan Yu, Jung H. Kim, Bo Han, Patrick Tan, Chandan Kumar-Sinha, Robert J. Lonigro, Nallasivam Palanisamy, Christopher A. Maher, Arul M. Chinnaiyan

A class of proteins required for membrane trafficking and cytokinesis in eukaryotes is also unexpectedly required in some Archaea for cell division.

Authors: Rachel Y. Samson, Takayuki Obita, Stefan M. Freund, Roger L. Williams, Stephen D. Bell

The center is the newest frontier in the city’s campaign to reduce its dependence on Wall Street, as some of the biggest banks in New York have collapsed.

Biotech companies, some of the riskiest stock around because most experimental drugs fail, have been negatively impacted by the financial crisis.

The Food and Drug Administration’s new regulations to approve genetically engineered animal products should be a boon for both consumers and producers.

Fluidigm’s offering, which it hopes to make on Thursday unless market conditions force it to withdraw, is underwritten by Morgan Stanley.

Genentech said it would spend up to $371 million on retention bonuses to keep its employees from leaving because of the possible acquisition of the company by its majority shareowner, Roche.

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8; London AIM: PAI) today announces that it has successfully completed a Phase I study with its intravenous sedative/anaesthetic CNS 7056. The study was completed ahead of schedule because the target criterion, more than 50% of the volunteers reaching loss of consciousness for more than 5 minutes, was reached in the 9th of the 10 planned cohorts.

Second Sight® Medical Products, Inc., the leading developer of retinal prostheses for the blind, announced that it will increase patient enrollment for the ArgusTM II Retinal Implant study throughout clinical trials sites within Europe. The three-year feasibility study is currently underway in the United States, Europe and Mexico for people with Retinitis Pigmentosa (RP), a genetic eye disease that causes blindness.

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it presented positive data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 14th Annual Connective Tissue Oncology Society (CTOS) meeting held in London, UK, November 13 to 15. Also presented was an update of the data from the Phase II trial of palifosfamide used as a single agent in advanced sarcoma.

Applied Pharma Research sa (APR), and Fidia Farmaceutici SpA (Fidia) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for the development of a 140mg Diclofenac Sodium Matrix Patch for the topical treatment of acute pain due to minor strains, sprains and contusions.

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has begun recruitment for its Phase 2 clinical trial of the Company's lead oncology agent PV-10 at a sixth major center located at the California Pacific Medical Center, in San Francisco, CA. David Minor, M.D. will serve as principal investigator at the new center covering the western United States.

Head of Google UK Dennis Woodside on the firm's rise to success and its plans for personal phone numbers.

Astronauts Heidemarie Stefanyshyn-Piper and Stephen Bowen have taken part in the first of four spacewalks of the Endeavour's current mission to the International Space Station.

Greenhouse gas emissions in the world's 40 leading industrialised nations rose more than 2% between 2000 and 2006, even though cuts had been promised, according to a UN climate change agency report.

New South Wales Primary Industries Minister Ian Macdonald on the locust swarms affecting Australia.

Bee keepers are warning that there could be no domestically produced honey left on supermarket shelves by Christmas.

Evolution assumes that extinction is forever. Maybe not. Henry Nicholls asks what it would take to bring the woolly mammoth back from the dead.

The multi-million dollar 1000 Genomes project is set to be finished in a year.

Findings reignite debate over genetically modified crops.

Frozen assets compound deCODE's financial woes.

Eric Schadt revels in making people uncomfortable with his science. Bryn Nelson reports how the bioinformatics rabble-rouser hopes to charge ahead in the face of his company's disintegration.